On December 22, 2023, Martina Flammer, the Chief Medical Officer of Insmed Incorporated (INSM, Financial), sold 28,310 shares of the company's stock, according to a recent SEC Filing. The transaction was executed with the stock priced at $30 per share, resulting in a total sale amount of $849,300.
Insmed Incorporated is a global biopharmaceutical company focused on the development and commercialization of therapies for patients with serious and rare diseases. The company's products are designed to address unmet medical needs, particularly in the areas of lung and infectious diseases.
Over the past year, the insider has sold a total of 46,285 shares and has not made any purchases of the company's stock. The recent sale by the insider is part of a broader trend observed over the past year, where there has been only 1 insider buy and 26 insider sells for Insmed Inc.
Shares of Insmed Inc were trading at $30 on the day of the insider's recent transaction, giving the company a market capitalization of $4.297 billion.
The stock's price-to-GF-Value ratio stands at 1.07, indicating that Insmed Inc is Fairly Valued based on its GF Value of $27.97. The GF Value is a proprietary intrinsic value estimate from GuruFocus, which is calculated considering historical trading multiples, a GuruFocus adjustment factor based on the company's past performance, and future business performance estimates from Morningstar analysts.
The insider trend image above reflects the recent insider selling and buying activities at Insmed Inc.
The GF Value image provides a visual representation of the stock's current valuation in relation to its GuruFocus Value.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
